109 related articles for article (PubMed ID: 35108789)
21. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
Rohr UP; Herrmann P; Ilm K; Zhang H; Lohmann S; Reiser A; Muranyi A; Smith J; Burock S; Osterland M; Leith K; Singh S; Brunhoeber P; Bowermaster R; Tie J; Christie M; Wong HL; Waring P; Shanmugam K; Gibbs P; Stein U
Ann Oncol; 2017 Aug; 28(8):1869-1875. PubMed ID: 28460000
[TBL] [Abstract][Full Text] [Related]
23. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
[No Abstract] [Full Text] [Related]
24. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
Sinicrope FA; Foster NR; Yoon HH; Smyrk TC; Kim GP; Allegra CJ; Yothers G; Nikcevich DA; Sargent DJ
J Clin Oncol; 2012 Feb; 30(4):406-12. PubMed ID: 22203756
[TBL] [Abstract][Full Text] [Related]
25. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
[No Abstract] [Full Text] [Related]
26. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence.
Sinicrope FA; Nelson GD; Saberzadeh-Ardestani B; Segovia DI; Graham RP; Wu C; Hagen CE; Shivji S; Savage P; Buchanan DD; Jenkins MA; Phipps AI; Swallow C; LeMarchand L; Gallinger S; Grant RC; Pai RK; Sinicrope SN; Yan D; Shanmugam K; Conner J; Cyr DP; Kirsch R; Banerjee I; Alberts SR; Shi Q; Pai RK
Cancer Res Commun; 2024 May; 4(5):1344-1350. PubMed ID: 38709069
[TBL] [Abstract][Full Text] [Related]
27. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres.
Grant M; Haydon A; Au L; Wilkins S; Oliva K; Segelov E; Antill Y; Carne P; Ranchod P; Polglase A; Farmer C; Chin M; Wale R; Simpson P; Bell S; Skinner S; McMurrick P; Shapiro J
Int J Surg; 2018 Mar; 51():71-75. PubMed ID: 29367039
[TBL] [Abstract][Full Text] [Related]
29. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
31. Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.
Loh KW; Michael M; Zalcberg JR; Jefford M
Clin Colorectal Cancer; 2015 Sep; 14(3):192-7. PubMed ID: 26002619
[TBL] [Abstract][Full Text] [Related]
32. [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].
Chen K; Liang H; Peng J; Zheng Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1300-1305. PubMed ID: 30514676
[TBL] [Abstract][Full Text] [Related]
33. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
Sun CY; Chiang JM; Chen TC; Hung HY; You JF
World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
[TBL] [Abstract][Full Text] [Related]
34. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
Cancer; 2020 Sep; 126(18):4136-4147. PubMed ID: 32697360
[TBL] [Abstract][Full Text] [Related]
35. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
[TBL] [Abstract][Full Text] [Related]
36. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas.
Yoon HH; Orrock JM; Foster NR; Sargent DJ; Smyrk TC; Sinicrope FA
PLoS One; 2012; 7(8):e42274. PubMed ID: 22879926
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
39. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
40. Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer.
Baek DW; Kang BW; Lee SJ; Kim HJ; Park SY; Park JS; Choi GS; Baek JH; Kim JG
In Vivo; 2019; 33(2):649-657. PubMed ID: 30804154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]